STOCK TITAN

Viridian Therapeutics: Paradigm reports 7.3% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Viridian Therapeutics, Inc. (VRDN) ownership disclosures report 8,257,672 common shares, or 7.3%, beneficially owned by Paradigm BioCapital Advisors LP, its general partner Paradigm BioCapital Advisors GP LLC, and Senai Asefaw, M.D., as of September 30, 2026. The Adviser, its general partner and Senai Asefaw may be deemed beneficial owners of shares directly held by Paradigm BioCapital International Fund Ltd. and one or more separately managed accounts.

The Fund separately reported beneficial ownership of 7,278,105 shares, or 6.4%. The percentages are based on 113,292,269 shares outstanding as of August 3, 2026. The reporting persons’ figures overlap and should not be added together.

Beneficial ownership attributed to Adviser, general partner and Senai Asefaw 8,257,672 shares; 7.3% As of September 30, 2026; overlapping reporting-person figures
Fund beneficial ownership 7,278,105 shares; 6.4% Paradigm BioCapital International Fund Ltd., as of September 30, 2026
Shares outstanding 113,292,269 shares As of August 3, 2026; basis for the reported ownership percentages
beneficially owned financial
"Aggregate Amount Beneficially Owned by Each Reporting Person"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Sole Voting Power financial
"Sole Voting Power 8,257,672.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
Sole Dispositive Power financial
"Sole Dispositive Power 8,257,672.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many VRDN shares did Paradigm BioCapital report as beneficially owned?

Paradigm BioCapital Advisors LP, its general partner and Senai Asefaw, M.D. each reported beneficial ownership of 8,257,672 shares, or 7.3%, as of September 30, 2026. These overlapping reports should not be added together.

How many VRDN shares did Paradigm BioCapital International Fund report?

Paradigm BioCapital International Fund Ltd. reported beneficial ownership of 7,278,105 shares, or 6.4%, as of September 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





92790C104

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G




Comment for Type of Reporting Person: limited liability company


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Paradigm BioCapital Advisors LP
Signature:/s/ David K. Kim
Name/Title:David K. Kim / Authorized Signatory
Date:11/16/2026
Paradigm BioCapital Advisors GP LLC
Signature:/s/ David K. Kim
Name/Title:David K. Kim / Authorized Signatory
Date:11/16/2026
Senai Asefaw, M.D.
Signature:/s/ Senai Asefaw, M.D.
Name/Title:N/A
Date:11/16/2026
Paradigm BioCapital International Fund Ltd.
Signature:/s/ David K. Kim
Name/Title:David K. Kim / Authorized Signatory
Date:11/16/2026

Keep reading